Prevalence and triggers of self-reported nasal hyperreactivity in adults with asthma.
AR, allergic rhinitis
Asthma
Atopy
BHR, bronchial hyperreactivity
Bronchial hyperreactivity
FEV1, forced expiratory volume in one second
NHR, nasal hyperreactivity
Nasal hyperreactivity
Symptom severity
VAS, visual analogue scale
Journal
The World Allergy Organization journal
ISSN: 1939-4551
Titre abrégé: World Allergy Organ J
Pays: United States
ID NLM: 101481283
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
08
11
2019
revised:
15
05
2020
accepted:
17
05
2020
entrez:
10
7
2020
pubmed:
10
7
2020
medline:
10
7
2020
Statut:
epublish
Résumé
Nasal hyperreactivity (NHR) is a common feature of various rhinitis subtypes and represents a novel phenotype of rhinitis. It is being reported in two-thirds of adult rhinitis patients irrespective of the atopic status. Data on the prevalence of NHR in patients with asthma are lacking, as well as the nature of evoking triggers. Postal questionnaires were distributed to an unselected group of asthmatic patients in Leuven (Belgium, n = 190) and completed by 114 patients. In Mexico City (Mexico) and Brasov (Romania), respectively, 97 out of 110 and 80 out of 100 asthmatic patients attending the outpatient clinic completed the questionnaire. Non-asthmatic volunteers were recruited amongst university and hospital co-workers in Leuven (n = 53). The presence of self-reported NHR, the type of triggers evoking nasal and bronchial symptoms, medication use, self-reported allergy, and environmental factors were evaluated. Overall, 69% of asthma patients reported NHR, with 32% having more than 4 triggers evoking NHR. These triggers included mainly exposure to temperature and humidity changes, cigarette smoke, and strong odours. A higher prevalence of NHR was detected in allergic compared to non-allergic asthma patients (73% vs. 53% p < 0.01). The prevalence of NHR correlated with asthma severity, ranging from 63% (VAS ≤3) to 81% (VAS ≥7). BHR was found more frequently in patients with NHR compared to without NHR (89% vs. 53%, p < 0.0001). NHR represents a clinical phenotype of upper airway disease affecting over two-thirds of asthma patients and correlates with asthma severity. Targeting NHR in patients with asthma is often overlooked and should be reinforced in the future to achieve better symptom control.
Sections du résumé
BACKGROUND
BACKGROUND
Nasal hyperreactivity (NHR) is a common feature of various rhinitis subtypes and represents a novel phenotype of rhinitis. It is being reported in two-thirds of adult rhinitis patients irrespective of the atopic status. Data on the prevalence of NHR in patients with asthma are lacking, as well as the nature of evoking triggers.
METHODS
METHODS
Postal questionnaires were distributed to an unselected group of asthmatic patients in Leuven (Belgium, n = 190) and completed by 114 patients. In Mexico City (Mexico) and Brasov (Romania), respectively, 97 out of 110 and 80 out of 100 asthmatic patients attending the outpatient clinic completed the questionnaire. Non-asthmatic volunteers were recruited amongst university and hospital co-workers in Leuven (n = 53). The presence of self-reported NHR, the type of triggers evoking nasal and bronchial symptoms, medication use, self-reported allergy, and environmental factors were evaluated.
RESULTS
RESULTS
Overall, 69% of asthma patients reported NHR, with 32% having more than 4 triggers evoking NHR. These triggers included mainly exposure to temperature and humidity changes, cigarette smoke, and strong odours. A higher prevalence of NHR was detected in allergic compared to non-allergic asthma patients (73% vs. 53% p < 0.01). The prevalence of NHR correlated with asthma severity, ranging from 63% (VAS ≤3) to 81% (VAS ≥7). BHR was found more frequently in patients with NHR compared to without NHR (89% vs. 53%, p < 0.0001).
CONCLUSION
CONCLUSIONS
NHR represents a clinical phenotype of upper airway disease affecting over two-thirds of asthma patients and correlates with asthma severity. Targeting NHR in patients with asthma is often overlooked and should be reinforced in the future to achieve better symptom control.
Identifiants
pubmed: 32642023
doi: 10.1016/j.waojou.2020.100132
pii: S1939-4551(20)30035-1
pii: 100132
pmc: PMC7334478
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100132Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
All authors state they have no conflict of interest in relation to this study and the results described in the manuscript.
Références
Allergy. 2018 Jan;73(1):248-250
pubmed: 28712109
Clin Exp Allergy. 2013 Aug;43(8):881-8
pubmed: 23889242
Rhinology. 2006 Sep;44(3):179-87
pubmed: 17020064
J Allergy Clin Immunol. 2016 Apr;137(4):1043-1053.e5
pubmed: 26846377
Clin Otolaryngol Allied Sci. 1991 Apr;16(2):133-7
pubmed: 2070527
Allergy. 2015 Feb;70(2):187-94
pubmed: 25358760
Allergy. 2018 Sep;73(9):1784-1791
pubmed: 29624710
Rhinology. 2016 Jun;54(2):129-33
pubmed: 27017484
J Asthma. 2013 Jun;50(5):514-21
pubmed: 23506422
Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 1):1748-55
pubmed: 9620901
Rhinology. 2012 Sep;50(3):227-35
pubmed: 22888478
Allergy. 2013 Nov;68(11):1427-34
pubmed: 24118053
Thorax. 2013 Oct;68(10):906-13
pubmed: 23821393
J Allergy Clin Immunol. 2017 Aug;140(2):437-446.e2
pubmed: 28389389
J Allergy Clin Immunol. 2006 Sep;118(3):551-9; quiz 560-1
pubmed: 16950269
Eur Respir J. 2017 May 1;49(5):
pubmed: 28461290
Respir Res. 2017 Feb 23;18(1):39
pubmed: 28231834
Allergy. 2018 May;73(5):1084-1093
pubmed: 29121401
J Allergy Clin Immunol. 2017 Oct;140(4):950-958
pubmed: 28602936
Allergy. 2018 Aug;73(8):1597-1608
pubmed: 29377177
Rhinology. 2007 Jun;45(2):144-7
pubmed: 17708462
Rhinology. 2017 Mar 1;55(1):34-38
pubmed: 28019644
Clin Exp Allergy. 1997 Jul;27(7):796-801
pubmed: 9249272
Allergy. 2018 Jan;73(1):8-16
pubmed: 28599081
Allergo J Int. 2017;26(1):16-24
pubmed: 28217433
J Allergy Clin Immunol. 2014 May;133(5):1332-9, 1339.e1-3
pubmed: 24139494
Rhinology. 2018 Sep 1;56(3):279-287
pubmed: 29561921
Laryngoscope. 2012 Dec;122(12):2615-20
pubmed: 22865676